Evidence map›Paper›PMID 37874401›Full record

Trial reportEuropean journal of pediatrics2024

Topical administration of S. salivarius 24SMB-S. oralis 89a in children with adenoidal disease: a double-blind controlled trial.

Francesco Folino, Daniele Di Pasquale, Paola Marchisio, Lorenzo Pignataro, Pasquale Capaccio, Lorenzo Gaini, Ludovica Battilocchi, Samantha Bosis, Sara Torretta

Open access · hybridAbstract readRandomized Controlled Trial
In one paragraph

Trial report in European journal of pediatrics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Francesco FolinoFondazione IRCCS Cà Granda Ospedale Maggiore Policlinico di Milano, Milan, Italy.
Daniele Di PasqualeFondazione IRCCS Cà Granda Ospedale Maggiore Policlinico di Milano, Milan, Italy.
Paola MarchisioFondazione IRCCS Cà Granda Ospedale Maggiore Policlinico di Milano, Milan, Italy.
Lorenzo PignataroFondazione IRCCS Cà Granda Ospedale Maggiore Policlinico di Milano, Milan, Italy.
Pasquale CapaccioFondazione IRCCS Cà Granda Ospedale Maggiore Policlinico di Milano, Milan, Italy.
Lorenzo GainiFondazione IRCCS Cà Granda Ospedale Maggiore Policlinico di Milano, Milan, Italy.
Ludovica BattilocchiFondazione IRCCS Cà Granda Ospedale Maggiore Policlinico di Milano, Milan, Italy.
Samantha BosisFondazione IRCCS Cà Granda Ospedale Maggiore Policlinico di Milano, Milan, Italy.
Sara TorrettaFondazione IRCCS Cà Granda Ospedale Maggiore Policlinico di Milano, Milan, Italy. sara.torretta@unimi.it.
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico · ITUniversity of Milan · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic adenoiditis (CA) is generally sustained by some infectious foci mainly located within the nasopharynx or in the deep adenoidal pads and it is characterized by a complex interplay between bacterial species. The aim of this study was to assess the efficacy and safety of the topical nasal administration of a probiotic compound based on S. salivarius 24SMB and S. oralis 89a in children with CA in terms of reduction in: the number of acute adenoidal infections (primary outcome), and in the blockage of the nasopharynx space by hypertrophic adenoids (secondary outcome). A prospective, double-blind, 1:1 randomized controlled study was performed to test the effectiveness of a 90-day treatment with Rinogermina spray (DMD ITALIA s.r.l, Rome), 1 puff each nostril twice a day for 90 days, to nasal spray placebo in children with CA (in terms of number of acute exacerbations and blockage of nasopharynx space assessed after 90 days of treatment- T1, and 90 days later- T2). The final analysis was based on 152 children (males = 48.0%; mean age = 49.2 ± 14.1 months). Compared to the baseline, no significant differences in terms of number of acute exacerbations at T1 and T2 follow-up visits were detected in both groups. After treatment, a significant reduction in the blockage of nasopharynx space by hypertrophic adenoids (0.002 < p-value < 0.007) compared to the baseline was attested in the study group at T1 and T2, but not in the control group.

conclusionsOur findings document a positive effect of Rinogermina spray in achieving reduction in the blockage of nasopharynx space by hypertrophic adenoids, thus suggesting that its use into the integrated therapeutic management of children with CA could be of a certain utility. WHAT IS KNOWN: • Chronic adenoiditis in children results from an imablance in baterial homeostasis at the nasophaynx, with impairment in respiratory microbiota. • The modulatory effect of target transnasal bacteriotheray by means of S. salivarius has been considered in children with chronic adenoiditis in children with recurrent acute otitis media with preliminary positive results. WHAT IS NEW: • This randomized controlled study, specifically designed on a cohrt of children with chronic adenoiditis, documents a certain effectiveness of the probiotic treatment in achieving a reduction in the grade of adenoidal hypertropy, compared to placebo.

Indexed as

AdenoidsOtitis MediaAdministration, IntranasalAdministration, TopicalChildChild, PreschoolHumansHypertrophyMaleProspective StudiesAdenoidsChildrenOtitis

Identifiers

PMID37874401
PMCPMC10857951
OpenAlexW4387893118

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.